interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Tamoxifen Citrate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Tamoxifen Citrate, and who makes it?

Tamoxifen Citrate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 5 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 8.9 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Tamoxifen Citrate2 dosage-form groups in the Orange Book
5generic makers listed
  1. Tamoxifen Citrate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 5 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 8.9 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Every brand product here is listed as discontinued. 5 generic makers with 10 generic products listed as marketed; the first generic approval is dated 20 February 2003.

19901995200020052010201520202025203005brand 1994Actavis Laboratories Fl Inc, first approval 20 February 2003Dr Reddys Laboratories Sa, first approval 20 February 2003Mylan Pharmaceuticals Inc, first approval 20 February 2003Zydus Pharmaceuticals Usa Inc, first approval 27 October 2017Eugia Pharma Specialities Ltd, first approval 14 August 2020data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Actavis Laboratories Fl Inc20 February 20032
Dr Reddys Laboratories Sa20 February 20032
Mylan Pharmaceuticals Inc20 February 20032
Zydus Pharmaceuticals Usa Inc27 October 20172
Eugia Pharma Specialities Ltd14 August 20202

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Soltamox. No generic is listed as marketed.

20052010201520202025203001brand 2005data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.